Large B Cell Lymphoma

P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting

Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol...Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.

P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025

Moreover, these groups were identified using surrogate immunohistochemical markers: EBNA2, PDL1, and IDO1. In conclusion, the molecular studies assessing tumor-host interaction enhances understanding of the EBV+ large B-cell lymphoma spectrum and benefits pathological diagnosis and clinical management.

P3, N=400, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting

P1/2, N=20, Not yet recruiting, Seoul National University Hospital

P1, N=24, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2028 --> Aug 2028 | Initiation date: Oct 2025 --> Feb 2026 | Trial primary completion date: Jul 2027 --> Nov 2027

From a safety perspective, much progress has been made in reducing the burden of side effects and broadening access; however, barriers remain before TCE therapies can be widely available to all patients. This brief review addresses some of the latest strategies being tested to elevate TCE therapies as pillars of immunotherapy for B-NHL.

P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P2, N=20, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Dec 2025

Clinicians should maintain a high index of suspicion for central nervous system lymphoma in cases of relapsing myelitis unresponsive to conventional immunotherapy and consider timely biopsy when clinically feasible. Heightened awareness of sentinel lesions may facilitate early recognition and improve outcomes in patients with PCNSL.

The patient achieved complete remission with R-CHOP therapy, aligning with LBCL-IRF4-R's favorable prognosis. This case underscores the need for integrated morphology, immunophenotyping, and NGS to resolve complex diagnostic challenges. It presents a key diagnostic pitfall where secondary 11q aberrations in LBCL-IRF4-R can mimic HGBL-11q, revealing limitations of current genetic algorithms and advocating for expanded molecular diagnostic criteria.